| Autor: |
Schück S; Laboratoire de Pharmacologie Expérimentale et Clinique, Université de Rennes I - Faculté de Médecine, CS 34317, 35 043 Rennes cedex, France., Bentué-Ferrer D, Kleinermans D, Reymann JM, Polard E, Gandon JM, Allain H |
| Jazyk: |
angličtina |
| Zdroj: |
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2002 Feb; Vol. 16 (1), pp. 57-65. |
| DOI: |
10.1046/j.1472-8206.2002.00070.x |
| Abstrakt: |
Piribedil is a dopamine agonist acting on D2 and D3 central nervous system dopamine receptors. This drug has been administered to 12 young healthy male volunteers (age 22 +/- 2 years) according to a single center randomized, double-blind, two ways cross-over, placebo controlled trial, including a washout period of one week. Placebo and piribedil were administered by a single intravenous infusion over 2 h (3 mg). Psychomotor performance and cognitive functions were assessed through a standardized and computerized psychometric tests battery and a continuous electroencephalogram (EEG) mapping. Piribedil improved simple reaction time (P=0.02), immediate (P=0.045 and 0.004), and delayed free recall (P=0.05), dual coding test (P=0.02) and increased theta and fast beta waves on the EEG (P < 0.05 and 0.001, respectively). No deleterious effect was observed on the tests exploring attention and concentration via the other procedures. It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
